Mylan CEO Defends EpiPen Price Hike
WASHINGTON (AP) — The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens.
She’s signaling that the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers.
In testimony for Congress, CEO Heather Bresch says she believes Mylan has struck a balance between price and access to the drug.
The price of EpiPens has grown to $608 for a two-pack, an increase of more than 500 percent since 2007.
Bresch says the company does not want to go back to a time when awareness of allergic reactions was much lower and many schools did not stock the drug.